Hidden Conflicts? Pharma Payments to FDA Advisers After Drug Approvals Spark Ethical Concerns
Hidden Conflicts? Pharma Payments to FDA Advisers After Drug Approvals Spark Ethical Concerns
In examining compensation records from drug companies to physicians who advised FDA, Science found widespread after-the-fact payments or research support to panel members. The agency's safeguards against potential conflicts of interest are not designed to prevent such future financial ties.